China’s Economic Stimulus Package Expected To Boost Health Care Sector
This article was originally published in The Tan Sheet
Executive Summary
China's plan to inject 4 trillion yuan to stimulate economic growth and counter the effects of the global financial crisis is expected to boost the health care sector and propel medical system reforms
You may also be interested in...
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.
New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus In Troubled Financial Seas
GlaxoSmithKline provides leading-edge vaccine technology and equipment, along with an injection of cash totaling almost $30 million, while Neptunus contributes its production facilities and access to the Chinese market.
Will Being On China’s New Essential Drugs List Be A Boon Or A Bane?
Pharma execs debate the issue while awaiting release of the pared-down list, now anticipated sometime in June.